Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile.
Rogliani PaolaFrancesco CavalliAlfredo ChettaMario CazzolaLuigino CalzettaPublished in: Journal of asthma and allergy (2022)
Triple FDC is a safe pharmacological therapy in severe asthmatic patients; it is characterized by a favourable safety profile and few potential drawbacks, namely, the increased risk of vascular SAEs, that certainly are worthy of future investigations.
Keyphrases
- combination therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- lung function
- chronic obstructive pulmonary disease
- prognostic factors
- peritoneal dialysis
- human health
- early onset
- high resolution
- risk assessment
- stem cells
- patient reported outcomes
- mass spectrometry
- climate change
- muscular dystrophy
- smoking cessation
- cell therapy